急性髓系白血病患者化疗后继发感染的临床特征及危险因素分析

doi:10.3969/j.issn.1006-5253.2022.06.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2955 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective To explore the clinical characteristics and risk factors of secondary infection in patients with acute myeloid leukemia (AML) after chemotherapy.Methods Patients with AML undergoing chemotherapy in a hospital from March 2021 to April 2022 were enrolled as the research objects. The secondary infection after chemotherapy was statistically analyzed. The infection characteristics and clinical characteristics in both groups were analyzed. Multivariate regression was used to analyze the risk factors of secondary infection in AML patients after chemotherapy.Results Among 186 AML patients, 114 cases were infected after chemotherapy, and the infection rate was 61.29%. Among 114 patients with AML secondary infection, 46 strains of pathogenic bacteria were isolated, In the 114 AML patients with secondary infection, there were 46 strains of pathogens, including 12 strains of Gram-positive bacteria (26.09%), 25 strains of Gram-negative bacteria (54.35%) and 9 strains of fungi (19.57%). Logistic regression analysis showed that age>40 years old (OR=2.265, 95%CI:1.155-4.441), diabetes mellitus (OR=4.529, 95%CI: 1.48-13.863), WBC≤1×10⁹/L (OR=2.818, 95%CI: 1.246-6.375), agranulocytosis time>7 d (OR=2.454, 95%CI: 1.232-4.891) and ratio of bone marrow blast cells>50% (OR=2.908, 95%CI: 1.189-7.109) were all independent risk factors of secondary infection.Conclusion The incidence of secondary infection is high in AML patients after chemotherapy. Clinically, early prevention and symptomatic treatment can be carried out for patients with age>40 years old, diabetes mellitus, WBC ≤1×10⁹/L, agranulocytosis time>7 d and ratio of bone marrow blast cells>50%.

Key words： acute myeloid leukemia infection risk factor

Received: 26 July 2022

PACS:

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Min
	Li Linjie

Cite this article:

Liu Min,Li Linjie. Clinical characteristics and risk factors of secondary infection in patients with acute myeloid leukemia after chemotherapy[J]. journal1, 2022, 29(6): 424-427.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2022.06.004 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2022/V29/I6/424

［1］MALEKI BEHZAD M, ABBASI M, OLIAEI I, et al. Effects of lifestyle and environmental factors on the risk of acute myeloid leukemia: Result of a hospital-based case-control study［J］. J Res Health Sci, 2021, 21(3):e00525. DOI:10.34172/jrhs.2021.58.

［2］HWANG S M. Classification of acute myeloid leukemia［J］. Blood Res, 2020, 55(s1):S1-S4. DOI:10.5045/br.2020.s001.

［3］SHAHRABI S, GHANAVAT M, BEHZAD M M, et al. CD markers polymorphisms as prognostic biomarkers in hematological malignancies［J］. Oncol Rev, 2020, 14(2):466. DOI:10.4081/oncol.2020.466.

［4］RAFIEEMEHR H, CALHOR F, ESFAHANI H, et al. Risk of acute lymphoblastic leukemia: Results of a case-control study［J］. Asian Pac J Cancer Prev, 2019, 20(8):2477-2483. DOI:10.31557/apjcp.2019.20.8.2477.

［5］BR-CK O, DUFVA O, HOHTARI H, et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival［J］. Blood Adv, 2020, 4(2):274-286. DOI:10.1182/bloodadvances.2019000792.

［6］孟广强，陈以娟，郭慧霞，等．高白细胞急性髓系白血病早期死亡临床分析［J］．内科急危重症杂志，2019，25(2)：113-115．DOI:10.11768/nkjwzzzz20190207.[ZK)]

［7］MULANOVICH V, KONTOYIANNIS D P. Acute myeloid leukemia and the infectious diseases consultant［J］. Leuk Lymphoma, 2018, 59(6):1284-1291. DOI:10.1080/10428194.2017.1365861.

［8］胡霞，陈乃耀．急性髓系白血病化疗合并感染的危险因素及风险评估［J］．临床血液学杂志，2021，34(3)：215-219．DOI:10.13201/j.issn.1004-2806.2021.03.015.

［9］中华医学会血液学分会白血病淋巴瘤学组．成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南：2017年版［J］．中华血液学杂志，2017，38(3)：177-182．DOI:10.3760/cma.j.issn.0253-2727.2017.03.001.

［10］中华人民共和国卫生部．医院感染诊断标准：试行［A］．中华医学杂志，2001，81(5)：314-320． DOI:10.3760/j:issn:0376-2491.2001.05.027.

［11］李雅，陈瑜，李军民．老年急性髓系白血病的治疗进展［J］．内科理论与实践，2019，14(6)：391-394．DOI:10.16138/j.1673-6087.2019.06.013.

［12］U M M, HAO X H, CONG L, et al. The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China［J］.Medicine(Baltimore),2019,98(50):e18196. DOI:10.1097/MD.0000000000018196.

［13］唐晶，张荣，李冬梅．急性髓系白血病患者化疗后院内感染危险因素及护理措施分析［J］．现代医学，2020，48(11)：1448-1451．

［14］韦杰敏，赖小璇，章忠明，等．急性白血病患者细菌性血流感染临床和病原学分析［J］．中国实验血液学杂志，2019，27(6)：1774-1778．DOI:10.19746/j.cnki.issn1009-2137.2019.06.011.

［15］阮敏，黄震琪，吴炜，等．急性髓系白血病并感染病人血清CD64、IL-6、PDW水平与病原菌分布特征、感染预后的关联性［J］．蚌埠医学院学报，2022，47(3)：340-345．DOI:10.13898/j.cnki.issn.1000-2200.2022.03.017.

［16］BALLO O, TARAZZIT I, STRATMANN J, et al. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy［J］. PLoS One, 2019, 14(1):e0210991. DOI:10.1371/journal.pone.0210991.

［17］ALDOSS I, DADWAL S, ZHANG J Y, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents［J］. Blood Adv, 2019, 3(23):4043-4049. DOI:10.1182/bloodadvances.2019000930.

［18］张晓波，谢佳，王浩，等．成人急性髓系白血病患者化疗后院内感染的危险因素［J］．海南医学，2019，30(15)：1914-1917．DOI:10.3969/j.issn.1003-6350.2019.15.003.

［19］汪梅花，赵康，葛繁梅．成人急性髓系白血病患者化疗后发生院内感染的影响因素［J］．中国医刊，2019，54(9)：993-995．DOI:10.3969/j.issn.1008-1070.2019.09.021.

［20］LIEN M Y, CHOU C H, LIN C C, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study［J］. PLoS One, 2018, 13(6):e0197851. DOI:10.1371/journal.pone.0197851.

［21］HEINZ W J, BUCHHEIDT D, CHRISTOPEIT M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)［J］. Ann Hematol, 2017, 96(11):1775-1792. DOI:10.1007/s00277-017-3098-3.

［22］ARNOLD D E, MAUDE S L, CALLAHAN C A, et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients［J］. Pediatr Blood Cancer, 2020, 67(3):e28092. DOI:10.1002/pbc.28092.